Purdue Pharma has patented a tamper-resistant opioid analgesic dosage form with an extended-release matrix and specific dissolution rates. The solid oral dosage form includes key ingredients like magnesium stearate and polyethylene oxide, providing controlled release over time. GlobalData’s report on Purdue Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Purdue Pharma, Human telomerase RT biomarker was a key innovation area identified from patents. Purdue Pharma's grant share as of May 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Tamper resistant opioid analgesic extended release dosage form
A recently granted patent (Publication Number: US11964056B1) discloses a solid oral extended-release dosage form designed to provide controlled release of an active agent, particularly an opioid analgesic like oxycodone hydrochloride. The dosage form consists of an extended-release matrix containing specific ingredients such as magnesium stearate, butylated hydroxytoluene, and polyethylene oxide (PEO) with a defined molecular weight range. The formulation includes a film coat and is designed to release the active agent within specific timeframes when tested in simulated gastric fluid. Additionally, the dosage form undergoes expansion during the curing process, as indicated by a decrease in density, ensuring its integrity and performance.
Furthermore, the patent claims detail specific parameters for the composition and performance of the solid oral extended-release dosage form, including the molecular weight range of PEO, curing temperature and time, tablet hardness, and resistance to cracking. The dosage form is specifically tailored for opioid analgesics like oxycodone hydrochloride, with precise specifications for the release rate and plasma concentration levels. The inclusion of PEO in the formulation plays a crucial role in achieving the desired extended-release properties, with variations in molecular weight impacting the overall performance of the dosage form. Overall, the patent highlights a novel formulation that addresses the need for controlled release of opioid analgesics, ensuring efficacy and safety in clinical use.
To know more about GlobalData’s detailed insights on Purdue Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
